Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer

This study is testing a three-drug combination — envafolimab (immunotherapy), fruquintinib (a targeted drug that cuts off blood supply to tumors), and chemotherapy — given before surgery (neoadjuvant treatment) for people with locally advanced stomach cancer or cancer at the junction of the stomach and esophagus. The goal is to shrink the cancer before surgery to improve surgical outcomes. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with locally advanced gastric (stomach) or gastroesophageal junction adenocarcinoma confirmed by tissue test - Your cancer is potentially removable with surgery but has grown into surrounding tissue (clinical stage cT2-T4b, with lymph node involvement, and no distant spread) - You have at least one measurable tumor on a scan - Your performance status and organ function meet the required minimums - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have already received treatment for stomach cancer - You do not meet performance status or organ function requirements Talk to your doctor to see if this trial is right for you.